BMO Capital Markets Reiterates Buy Rating for DexCom, Inc. (DXCM)

BMO Capital Markets reiterated their buy rating on shares of DexCom, Inc. (NASDAQ:DXCM) in a report issued on Friday morning. They currently have a $90.00 price objective on the medical device company’s stock.

A number of other research firms also recently issued reports on DXCM. BidaskClub downgraded shares of DexCom from a buy rating to a hold rating in a research note on Wednesday, July 5th. Zacks Investment Research raised shares of DexCom from a sell rating to a hold rating in a research note on Monday, August 14th. Piper Jaffray Companies reissued an overweight rating and issued a $78.00 price target (down from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. Oppenheimer Holdings, Inc. set a $92.00 target price on shares of DexCom and gave the company a buy rating in a research note on Wednesday, August 2nd. Finally, TheStreet raised shares of DexCom from a d rating to a c- rating in a research note on Wednesday, August 2nd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. DexCom has an average rating of Buy and a consensus target price of $87.64.

DexCom (NASDAQ DXCM) opened at 73.13 on Friday. The firm’s 50-day moving average price is $71.97 and its 200-day moving average price is $74.23. DexCom has a 1-year low of $57.68 and a 1-year high of $95.40. The firm’s market cap is $6.33 billion.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. During the same period in the prior year, the firm earned ($0.24) earnings per share. DexCom’s revenue was up 24.3% on a year-over-year basis. Equities research analysts anticipate that DexCom will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.themarketsdaily.com/2017/09/12/bmo-capital-markets-reiterates-buy-rating-for-dexcom-inc-dxcm.html.

In other news, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10. Following the sale, the executive vice president now owns 72,395 shares in the company, valued at $5,448,447.70. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total transaction of $113,375.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,979 shares of company stock worth $1,646,805. Corporate insiders own 1.70% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Advisor Group Inc. boosted its holdings in DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in DexCom in the first quarter worth approximately $136,000. IFP Advisors Inc boosted its holdings in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock worth $158,000 after purchasing an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in DexCom in the first quarter worth approximately $164,000. Finally, Independent Portfolio Consultants Inc. boosted its holdings in DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after purchasing an additional 9 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply